Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Trial Profile

Prevention of Postoperative Events Following Reversal With Sugammadex or Neostigmine

Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Feb 2017

At a glance

  • Drugs Sugammadex (Primary) ; Glycopyrrolate; Neostigmine
  • Indications Neuromuscular blockade
  • Focus Adverse reactions
  • Acronyms P-PERSoN
  • Most Recent Events

    • 06 Jul 2016 New trial record
    • 09 Jun 2016 Treatment section revised with change in dosing for neostigmine from 0.375mg/kg to 0.5mg/kg (comparator) to align with product information.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top